secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001437749-23-031280
Event type: earnings
Sentiment:  negative
Materiality: 0.82
Item codes: 1.01, 1.02, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree Q3 net loss $4.4M ($0.86/share); cash $7.4M, runway to Q1 2024
-----------------------------------------------------------------------

- Net loss of $4.4M ($0.86 per share) on 5.1M weighted-average shares; operating loss $4.7M.
- Cash and equivalents $7.4M as of Sep 30, expected to fund operations through Q1 2024.
- R&D expenses increased to $2.1M due to SEISMiC Extension study initiation; G&A stable at $2.6M.
- Entered new ATM agreement with Ladenburg for up to $2.05M stock sales; prior ATM terminated.
- Istaroxime program: SEISMiC Extension study underway; SCAI Stage C study expected to start Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774923031280/0001437749-23-031280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774923031280/wint20231108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer